EcoDrugPlus

Farnesyltransferase, Caax Box, Alpha

Ensembl ID : ENSPANG00000016458
Gene Symbol: FNTA
5 Cross references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Farnesyltransferase, Caax Box, Beta

Ensembl ID : ENSPANG00000025017
Gene Symbol: FNTB
5 Cross references
210 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Fatty Acid Amide Hydrolase

Ensembl ID : ENSPANG00000024429
Gene Symbol: FAAH
5 Cross references
131 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Fibroblast Growth Factor 2

Ensembl ID : ENSPANG00000022787
Gene Symbol: FGF2
5 Cross references
117 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Fibroblast Growth Factor Receptor 1

Ensembl ID : ENSPANG00000012485
Gene Symbol: FGFR1
5 Cross references
289 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSPANG00000020505
Gene Symbol: FGFR2
5 Cross references
217 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSPANG00000024533
Gene Symbol: FGFR3
5 Cross references
196 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Fibroblast Growth Factor Receptor 4

Ensembl ID : ENSPANG00000012360
Gene Symbol: FGFR4
5 Cross references
122 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSPANG00000009892
Gene Symbol: FLT1
5 Cross references
198 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Fms Related Receptor Tyrosine Kinase 3

Ensembl ID : ENSPANG00000009315
Gene Symbol: FLT3
5 Cross references
133 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSPANG00000016325
Gene Symbol: FLT4
5 Cross references
195 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Folate Hydrolase 1

Ensembl ID : ENSPANG00000034012
Gene Symbol: FOLH1
5 Cross references
210 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).